Proactive Investors
05 Oct 2026, 00:43 UTC · 3h ago
CSL strikes US$1.6 billion licensing deal for rare disease drug
Impact · against what's priced in
CSL has expanded its nephrology pipeline through a significant licensing deal for lixudebart, though the long-term profit split with Alentis limits the potential EPS accretion. The news is a positive growth catalyst, though tempered by the US$1.555 billion total potential cash outlay.
- CSL+0.50
No priced-in read yet
- In context
CSL is diversifying into nephrology and liver disease with a licensing deal for lixudebart, involving a US$355 million upfront payment and up to US$1.2 billion in milestones.
Read from the article alone
Search tags
